Mayo Clinic tests novel vaccine for aggressive brain tumors

October 22, 2007

A vaccine that has significantly increased life expectancy in early tests of patients with glioblastoma multiforme (GBM) − the most common, most aggressive form of brain cancer in adults − is now being offered through a clinical trial at Mayo Clinic in Jacksonville.

The vaccine represents a fresh and fairly simple approach to treating this cancer, says neurosurgeon Kent New, M.D., Ph.D., who will be leading the study at Mayo. About 40% of these tumors display a particular protein on their surface and the vaccine is designed to trick the patient’s immune system into thinking the protein is “foreign” in order to mount a killing response.

“We are pleased to have a new and promising therapy to offer patients who want to participate in this clinical trial,” says Dr. New. “The results, so far, have exceeded expectations.”

Earlier studies of the vaccine at the University of Texas M. D. Anderson Cancer Center and Duke University Medical Center showed that median survival for the 39 GBM patients tested increased by more than 50 percent compared to the typical outcome. Additionally, the time it took tumors to begin growing again was doubled.

Dr. New cautioned, however, that it is unknown whether the vaccine added to standard treatment (surgery followed by radiation and chemotherapy) will ultimately produce any better outcome than the standard treatment alone. “By comparing standard therapy plus the vaccine to standard therapy alone, we hope to determine the true benefit of the vaccine” he says.

According to the National Cancer Institute, more than 20,000 people in the U.S. will be diagnosed with a brain tumor in 2007 and almost 13,000 will die from the cancer. GBM, the most common primary brain tumor, is considered incurable; most patients die within a year of diagnosis.

Twenty or more centers nationwide will participate in the clinical trial initially, which is being sponsored by Celldex Therapeutics, the manufacturer of the vaccine, known as CDX-110. The study will be conducted in two stages. Approximately 90 patients will participate in the first portion, and if results show an improvement in disease-free survival for the CDX-110 treated patients, an additional 285 participants will be enrolled in the expanded study, which will include more sites.

Patients newly diagnosed with GBM who enroll in the study will have surgery at the participating center, and tumors will be examined to see if they express the mutated epidermal growth factor receptor variant III (EGFRvIII) protein. Researchers believe that this protein, which is not expressed on normal brain cells, pushes cancer development, which is one reason why glioblastomas are so aggressive. The vaccine uses synthetic versions of EGFRvIII to stimulate both cell-mediated immunity (T cells that attack invaders) and humoral immune responses (B cells that provide ongoing immune surveillance).

Participating patients whose tumors exhibit EGFRvIII will be randomized (selected by chance) either to standard treatment alone or standard treatment plus CDX-110, and the agents will be used until the tumor progresses or patients develop side effects from the treatment.

Source: Mayo Clinic

4.6 /5 (10 votes)  

Rank 4.6 /5 (10 votes)
Tags

Relevant PhysicsForums posts
  • Is Everyday Technology Killing Us?
    createdFeb 08, 2012
  • Exercise and weight loss
    createdFeb 08, 2012
  • Why do we have head aches? Our brains can't feel anything.
    createdFeb 07, 2012
  • "The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
    createdFeb 04, 2012
  • Oncolytic adenovirus
    createdFeb 04, 2012
  • Nutrition label stuffs and diets
    createdFeb 02, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Tenofovir, leading HIV medication, linked with risk of kidney damage

(Medical Xpress) -- Tenofovir, one of the most effective and commonly prescribed antiretroviral medications for HIV/AIDS, is associated with a significant risk of kidney damage and chronic kidney disease that increases over ...

Medicine & Health / Medications

created 1 hour ago | popularity not rated yet | comments 0 | with audio podcast

New tumor suppressor gene identified

A recent study published in Clinical Cancer Research suggests that the protein hVps37A suppresses tumor growth in ovarian cancer. The work, which was funded by the Austrian Science Fund FWF, shows, for th ...

Medicine & Health / Cancer

created 43 minutes ago | popularity 4 / 5 (1) | comments 0

Packard Children's has smallest child yet to get pacemaker

Jaya Maharaj was 15 minutes old when she was sent to surgery at Lucile Packard Children’s Hospital and given a pacemaker that saved her life. The tiny girl — born nine weeks early, weighing 3.5 pounds, ...

Medicine & Health / Cardiology

created 26 minutes ago | popularity not rated yet | comments 0

Social psychologist: Lust makes you smarter and evidence that seven deadly sins are good for you

(Medical Xpress) -- Good news for lovers on Valentine’s Day - the seven deadly sins, including Lust, are good for you. University of Melbourne social psychologist Dr Simon Laham uses modern research to make a compelling ...

Medicine & Health / Psychology & Psychiatry

created 2 hours ago | popularity 4.5 / 5 (2) | comments 0

Don't ignore kids' snores

(Medical Xpress) -- Your ears aren’t playing tricks on you – that is the sound of snoring you hear from the bedroom of your preschooler. Snoring is common in children, but in some cases it can be a symptom of a ...

Medicine & Health / Diseases

created 1 hour ago | popularity 5 / 5 (1) | comments 0


Transforming galaxies

(PhysOrg.com) -- Many of the Universe's galaxies are like our own, displaying beautiful spiral arms wrapping around a bright nucleus. Examples in this stunning image, taken with the Wide Field Camera 3 on ...

'Smart' microcapsules in a single step

(PhysOrg.com) -- A new, single-step method of fabricating microcapsules, which have potential commercial applications in industries including medicine, agriculture and diagnostics, has been developed by researchers ...

Building a 'blind-friendly' Internet

Rakesh Babu demonstrates how a blind person uses the Internet.

A continent ablaze in auroral and manmade light

The North American continent is literally set ablaze in a confluence of Auroral and Manmade light captured in spectacular new videos snapped by the astronauts serving aboard the International Space Station ...

Ethanol mandate not the best option

Many people are willing to pay a premium for ethanol, but not enough to justify the government mandate for the corn-based fuel, a Michigan State University economist argues.

Nanostructured electrodes for rechargeable sodium-Ion batteries

Highly efficient 3V cathodes for rechargeable sodium-ion batteries have been developed by users from Argonne National Laboratory's Materials Science, Chemical Sciences & Engineering, and X-ray Sciences Divisions, ...